PMID- 1361881
OWN - NLM
STAT- MEDLINE
DCOM- 19930204
LR  - 20131121
IS  - 0361-090X (Print)
IS  - 0361-090X (Linking)
VI  - 16
IP  - 5-6
DP  - 1992
TI  - Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific 
      transplantation antigen, cyclophosphamide, and interleukin-2.
PG  - 321-7
AB  - The anti-tumor effect of active specific chemoimmunotherapy, using 
      butanol-extracted tumor-specific transplantation antigen (TSTA), cyclophosphamide 
      (CY), and continuous intrasplenic infusion of interleukin-2 (IS-IL-2), was 
      assessed in a C3H/HeJ murine methylcholanthrene (MCA)-induced fibrosarcoma model. 
      Sole administration of TSTA induced tumor-specific, suppressor T cells in the 
      spleens of mice bearing 3-day established tumors. Concomitant low-dose (20 mg/kg) 
      CY treatment not only inhibited TSTA-mediated suppressor cell induction, but also 
      evoked splenic lymphocytes of tumor-bearing mice to display tumor-specific 
      cytotoxic activity. High-dose (200 mg/kg) CY abrogated the immunotherapeutic 
      benefit. The immune effectors generated by TSTA plus CY bear the Thy 1, L3T4, Lyt 
      2 phenotype. Continuous IS-IL-2 infusion in combination with TSTA and CY induced 
      tumor-specific Lyt 2+ cytolytic T cells, as well as the activation of L3T4+ 
      cytostatic T cells. Thus, a triple regimen using TSTA, CY, and IS-IL-2 appears to 
      augment CTL induction in tumor-bearing hosts undergoing stimulation of helper 
      elements by TSTA and inhibition of suppressor cells by CY.
FAU - Naito, K
AU  - Naito K
AD  - Second Department of Surgery, Kyoto Prefectural University of Medicine, Japan.
FAU - Nomi, S
AU  - Nomi S
FAU - Komichi, H
AU  - Komichi H
FAU - Ueda, Y
AU  - Ueda Y
FAU - Yamagishi, H
AU  - Yamagishi H
FAU - Oka, T
AU  - Oka T
FAU - Pellis, N R
AU  - Pellis NR
FAU - Kahan, B D
AU  - Kahan BD
LA  - eng
GR  - CA 29592/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Cancer Detect Prev
JT  - Cancer detection and prevention
JID - 7704778
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Histocompatibility Antigens)
RN  - 0 (Interleukin-2)
RN  - 0 (tumor-associated transplantation antigen)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/*immunology
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - Combined Modality Therapy
MH  - Cyclophosphamide/*administration & dosage
MH  - Cytotoxicity, Immunologic
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fibrosarcoma/*therapy
MH  - Histocompatibility Antigens/*immunology
MH  - Immunotherapy
MH  - Interleukin-2/*therapeutic use
MH  - Mice
MH  - Mice, Inbred C3H
MH  - Spleen/cytology
MH  - Survival Analysis
MH  - T-Lymphocyte Subsets/*immunology
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - T-Lymphocytes, Regulatory/immunology
EDAT- 1992/01/01 00:00
MHDA- 1992/01/01 00:01
CRDT- 1992/01/01 00:00
PHST- 1992/01/01 00:00 [pubmed]
PHST- 1992/01/01 00:01 [medline]
PHST- 1992/01/01 00:00 [entrez]
PST - ppublish
SO  - Cancer Detect Prev. 1992;16(5-6):321-7.